Valeo Pharma Inc.
VPHIF · OTC
7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | |
|---|---|---|---|---|
| Revenue | $12,601 | $14,129 | $13,539 | $13,108 |
| % Growth | -10.8% | 4.4% | 3.3% | – |
| Cost of Goods Sold | $9,167 | $11,382 | $11,437 | $12,476 |
| Gross Profit | $3,434 | $2,747 | $2,102 | $632 |
| % Margin | 27.3% | 19.4% | 15.5% | 4.8% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $5,386 | $5,207 | $5,086 | $5,516 |
| SG&A Expenses | $6,128 | $6,639 | $6,862 | $7,355 |
| Sales & Mktg Exp. | $742 | $1,440 | $1,776 | $1,839 |
| Other Operating Expenses | $526 | $0 | $259 | $411 |
| Operating Expenses | $6,654 | $6,639 | $7,121 | $7,766 |
| Operating Income | -$3,220 | -$3,892 | -$4,863 | -$7,134 |
| % Margin | -25.6% | -27.5% | -35.9% | -54.4% |
| Other Income/Exp. Net | -$4,972 | -$3,919 | -$2,009 | -$2,111 |
| Pre-Tax Income | -$8,192 | -$7,811 | -$6,872 | -$9,245 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8,192 | -$7,811 | -$6,872 | -$9,245 |
| % Margin | -65% | -55.3% | -50.8% | -70.5% |
| EPS | -0.083 | -0.079 | -0.08 | -0.098 |
| % Growth | -4.8% | 0.8% | 18.8% | – |
| EPS Diluted | -0.083 | -0.079 | -0.08 | -0.098 |
| Weighted Avg Shares Out | 98,676 | 98,675 | 86,138 | 94,019 |
| Weighted Avg Shares Out Dil | 98,675 | 98,675 | 86,138 | 94,019 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11 | $78 | $29 | $3,619 |
| Interest Expense | $3,887 | $3,843 | $3,806 | $3,755 |
| Depreciation & Amortization | $626 | $637 | $558 | $625 |
| EBITDA | -$3,679 | -$3,331 | -$4,305 | -$4,865 |
| % Margin | -29.2% | -23.6% | -31.8% | -37.1% |